Vice President Industry Relations Diplomat
In her role, Cheryl leads Diplomat’s Industry Relations team in finding partnerships and crafting health care solutions. Specifically, Cheryl leads Diplomat’s corporate efforts in identifying new opportunities within the pharmaceutical industry. She then collaborates with manufacturers to design services and distribution solutions that support their patients’ journey
Cheryl brings more than 25 years of industry experience, with work in independent and specialty pharmacy, as well as in managed care consulting and health care IT. Before joining Diplomat in July 2011, Cheryl worked as the senior director of clinical services at Sanovia Corporation, where she managed new product development and sales support. Prior to her tenure at Sanovia, she held roles with Priority HealthCare as a pharmacist-in-charge for oncology and lead pharmacist for pain management. Cheryl also founded C. Allen & Associates, a firm focused on managed care consulting, and Eden Drug Company, an independent pharmacy.
Cheryl earned her Bachelor of Science in pharmacy at Samford University’s McWhorter School of Pharmacy, and her MBA at Saint Joseph’s University Erivan K. Haub School of Business with a focus in pharmaceutical and health care marketing.
Alan Balch, PhD
Alan Balch, CEO Patient Advocate Foundation
Dr. Balch is the Chief Executive Officer of Patient Advocate Foundation and National Patient Advocate Foundation.
Dr. Balch has nearly fifteen years of executive leadership in the non-profit sector with an emphasis on consensus-building and collaboration. He has led numerous federal advocacy efforts on a range of issues both at the legislative and regulatory level over the years. He became the CEO of both PAF and NPAF in 2013. From 2006 - 2013, he served as the Vice President of the Preventive Health Partnership -- a national health promotion collaboration between the American Cancer Society, American Diabetes Association, and American Heart Association. Prior to his work with the Preventive Health Partnership, Dr. Balch was the Executive Director of Friends of Cancer Research.
Dr. Balch has served on the Executive Board of the Patient Advocate Foundation and National Patient Advocate Foundation since 2007. Dr. Balch also serves on numerous advisory boards and committees. He is a member of the External Advisory Board for the Hutchinson Institute for Cancer Outcomes Research (HICOR), a member of the Duke-Margolis Payment Reform Group, a member of the Robert Wood Johnson Foundation/Avalere Cost of Care Advisory Board, a member of the Quality and Outcomes Committee for the National Comprehensive Cancer Network (NCCN), and recently served as a member of the Guiding Committee for the Health Care Payment Learning and Action Network (LAN). Dr. Balch also serves on the Finance Committee and the Membership Committee for the National Health Council in Washington, DC, is a member of the National Committee for Quality Assurance’s Consumer Advisory Council, and sits on the inaugural board for The American Journal of Managed Care’s (AJMC) Institute for Value-Based Medicine (IVBM).
He earned his PhD in environmental studies with a concentration in political economy in 2003 from the University of California, Santa Cruz; his master’s degree in environmental sciences in 1997 from the University of Texas in San Antonio; his bachelor’s degree (cum laude) in biology in 1994 from Trinity University in San Antonio.
Dr. Balch is the Chief Executive Officer of Patient Advocate Foundation and National Patient Advocate Foundation.
Dr. Balch has a decade of executive leadership in the non-profit sector with an emphasis on consensus-building and collaboration. From 2006 - 2013, he served as the Vice President of the Preventive Health Partnership -- a national health promotion collaboration between the American Cancer Society, American Diabetes Association, and American Heart Association. Prior to his work with the Preventive Health Partnership, Dr. Balch was the Executive Director of Friends of Cancer Research.
He has led numerous federal advocacy efforts on a range of issues both at the legislative and regulatory level over the years. For example, he helped to organize and lead a coalition that successfully fought for improvements in the regulatory process for the review of cancer drugs at the Food and Drug Administration (FDA). He also contributed to the development of key federal policies related to the Affordable Care Act.
Dr. Balch serves on the Executive Board of the Patient Advocate Foundation and National Patient Advocate Foundation. Dr. Balch also serves on numerous advisory boards and committees. He is a member of the National Committee for Quality Assurance’s Wellness and Health Promotion Advisory Committee, a member of the Guiding Committee for the Health Care Payment Learning and Action Network (LAN), a member of the Advisory Board for the Patient Resource Cancer Guides, External Advisory Board member for the Hutchinson Institute for Cancer Outcomes Research (HICOR) and a member of the Robert Wood Johnson Foundation/Avalere Cost of Care Advisory Board. Dr. Balch also serves on the Finance Committee and the Membership Committee for the National Health Council in Washington, DC and recently accepted an invitation to join the inaugural board for The American Journal of Managed Care’s (AJMC) newest initiative, the Institute for Value-Based Medicine (IVBM). He is also a member of the 2017 Access to Innovation Forum Steering Committee for the Biotechnology Innovation Organization (BIO).
He earned his PhD in environmental studies in 2003 from the University of California, Santa Cruz; his master’s degree in environmental sciences in 1997 from the University of Texas in San Antonio; his bachelor’s degree (cum laude) in biology in 1994 from Trinity University in San Antonio.
Vice President Global Head Clinical Operations Strategy and Collaboration Sanofi
Victoria (Vicky) DiBiaso, is the Global Head of Clinical Operations Strategy & Collaboration within Sanofi’s R&D organization.
In her position, she manages an international team accountable for Sanofi’s development stage portfolio overseeing protocol optimization, global trial feasibility, competitive intelligence, the global investigator network and patient partnerships supporting an informed R&D model.
She and her team are responsible for ensuring collaborations with patient groups, as well as clinical trial physicians and coordinators, for protocol design considerations and robust patient community engagement strategies. She also has a large focus on clinical trial innovation ranging from technology to competitive intelligence to adequately inform decisions and patient facing activities. Their primary mandate is to optimize clinical trials from all aspects related to patients and investigator sites so that meaningful medications can come to market sooner.
Vicky has over 20 years of global experience ranging from phase I-IV drug development in rare disease biotech and multi-therapeutic specialty large pharma. She’s worked across multiple platforms such as devices, small molecules, biologics and gene-therapies.
Vicky is a frequent speaker at international industry conferences and is repeatedly quoted in industry publications related to clinical trial innovation and patient collaboration. In 2013 she was listed as one of CenterWatch’s Top 20 Innovators changing the face of clinical trials. In 2014, she was featured in the Wall Street Journal and has guest lectured on the role of patient, investigator and industry collaborations. She is a volunteer for the Michael J Fox Foundation for regional public engagement, a Research Ambassador and Team Fox co-captain. She also is a volunteer advisor for the Critical Path Institute (Parkinson’s).
Vicky holds a Master’s in Public Health and a Bachelor of Science in Nursing.
Mary Ann Dowd
Director Specialty Trade Mallinckrodt Pharmaceuticals
Maryann has over 25 years of experience in the healthcare sector spanning retail/specialty pharmacy, biotechnology and management consulting. Maryann’s focus has been to provide strategic and tactical direction to the optimize channel strategy across a number of franchises leveraging the specialty pharmacy distribution channel in support of the desired patient service model.
She has held various leadership roles at Mallinckrodt, Biogen Idec, PriceWaterhouse Coopers, EMD Serono and CVS Health. She has provided thought leadership in the management of multi-sponsored REMS programs and led an innovative limited distribution track and trace program designed to mitigate diversion and counterfeiting of high target biologics. Maryann has successfully launched several biologics products in to the specialty space and continues to provide expertise focused on continuous model improvement.
Maryann practiced pharmacy at CVS Health in Massachusetts after graduating from Mass College of Pharmacy. She is a member of the editorial board of Specialty Pharmacy Times and a member of the National Association of Specialty Pharmacy. She is a frequent speaker at key trade conferences.
Maryann is a Registered Pharmacist in Massachusetts.
Vice President, Managed Markets Intarcia Therapeutics, Inc.
Jeff Henderson has more than 26 years of pharmaceutical and biotech experience. He currently is the Vice President of Managed Markets at Intarcia Therapeutics, Inc, a position he has held since September 2015. In this position, Jeff is responsible for the Managed Markets Organization overseeing the Account Management, Payer Strategy, and the Government Reporting and Pricing functions.
Prior to joining Intarcia Therapeutics, Inc, Jeff spent 5 years at Vertex Pharmaceuticals, Inc and 19 years working for Pfizer, Inc. in various leadership positions. He has a broad range of experience and expertise leading commercial teams within the industry and specializes in new product commercialization, national and key account management, marketing, trade and distribution, specialty pharmacy, strategic planning, and pharmaceutical contract negotiation and pricing.
Jeff served as an officer in the United States Army for 15 years where he attained to rank of Major and is a graduate of the Virginia Military Institute with a Bachelor of Arts in History.
Todd Hobbs, MD, is vice president and chief medical officer for Novo Nordisk in North America, where he leads the organization’s focus on the implications of diabetes for the patient, healthcare system and healthcare professionals.
Dr. Hobbs provides overall medical guidance to Novo Nordisk’s diabetes- and obesity-related projects. He provides input into the clinical development and life-cycle management strategies for diabetes and obesity, as well as medical input into the R&D pipeline. He is involved with the optimization of relationships with top key opinion leaders and medical societies, and provides guidance to and participates in consultant advisory boards and key patient and professional associations and top thought leaders in diabetes.
Dr. Hobbs began his career at Novo Nordisk in 2004 as a field medical scientific director, then moving to the position of senior medical director, diabetes, in 2010. He led the Medical Affairs activities for all of Novo Nordisk’s current insulin products and devices, as well as supporting future insulin products through strategic and tactical activities.
In 2016, he started a 3 year term serving on the board for the American Medical Group Foundation (AMGF), the research foundation arm of the American Medical Group Association (AMGA).
Prior to working at Novo Nordisk, Dr. Hobbs had established a clinical practice based in Louisville, Kentucky, focusing on the intensive management of patients with diabetes of all ages, and served as chairman of the Medicine Department for a large Regional Medical Center in Kentucky. During this 10-year clinical career, he cared for more than 2,500 adults and children with diabetes, including outpatient and inpatient care, as well as intensive care.
Dr. Hobbs’ has a unique perspective on and personal dedication to the treatment of diabetes: his own experience with the disease began more than 25 years ago when he was diagnosed with type 1 diabetes. His passion for defeating the disease intensified even more with the diagnosis of one of his sons with the same condition at the age of five.
Vice President policy and research PHRMA
Tom Hubbard leads NEHI’s projects on comparative effectiveness research, patient medication adherence, and prevention and wellness initiatives. Mr. Hubbard leverages his policy and technology experience to examine ways the country’s health care system can be transformed, focusing on the promotion of medical innovation and the improvement of quality and efficiency in clinical care.
Mr. Hubbard came to NEHI after seven years at the Massachusetts Technology Collaborative (MTC), where he led industry-focused projects and supervised the annual publication of the MTC Index of the Massachusetts Innovation Economy. His work has included supervising the I-495 Technology Corridor Partnership, an industry-municipal collaboration on growth, and leading projects on broadband deployment, federal research funding advocacy, and nanotechnology.
Previously, Mr. Hubbard served as Executive Assistant for Economic Affairs to U.S. Senator John Kerry, as Deputy Director of Development for Massachusetts Governor Michael Dukakis, and as Director of Community Development and Planning for the City of Gardner, Massachusetts.
Mr. Hubbard graduated from Harvard College and holds a masters in public policy from Harvard’s Kennedy School of Government.
An internationally renowned thoracic surgeon, researcher, author and academician, Larry R. Kaiser, MD, is the leading health sciences executive at Temple University in Philadelphia, PA. He serves as CEO of the Temple University Health System, Senior Executive Vice President for the Health Sciences, and Dean of Temple University School of Medicine. Prior to joining Temple University Dr. Kaiser was the President of UTHealth, the University of Texas Health Science Center at Houston from 2008 until April 1, 2011.
Dr. Kaiser graduated from Tulane University School of Medicine in 1977 and completed his internship and residency in General Surgery as well as a fellowship in Surgical Oncology at the University of California (Los Angeles). He then completed a residency in cardiovascular surgery and thoracic surgery at the University of Toronto. Following that, he served as a thoracic surgeon at Memorial Sloan-Kettering Cancer Center and Assistant Professor of Surgery at Cornell University Medical College (New York) and was then recruited to Washington University School of Medicine (St. Louis) where he was promoted to Associate Professor of Surgery in 1990.
In 1991, Dr. Kaiser was recruited to the University of Pennsylvania (Philadelphia) where he held a succession of positions of increasing responsibility, including Associate Professor of Surgery, Chief of General Thoracic Surgery, Founder and Director of the university’s lung transplantation program, and Director of its Center for Lung Cancers and Related Disorders. In 1995, he was promoted to Professor of Surgery and in 1996 was named the Eldridge Eliason Professor of Surgery, the first individual to hold that chair. In 2001, following a national search, he was named the John Rhea Barton Professor and Chairman of the Department of the Department of Surgery at Penn.
In 2008, Dr. Kaiser was selected as the President of the University of Texas Health Science Center at Houston. There, he was responsible for six schools, more than 10,000 faculty and trainees, and a 900-member physician practice.
Dr. Kaiser’s research and clinical interests include lung cancer, malignant mesothelioma and mediastinal tumors. He is the author or co-author of 14 books and over 250 original papers.
Dr. Kaiser has served in a number of leadership capacities for professional societies and associations, and has been a director of the American Board of Surgery and the American Board of Thoracic Surgery. In 2004, he was elected to the Institute of Medicine of the National Academy of Sciences. His recent honors include citations in Castle Connolly’s “America’s Top Doctors for Cancer” 6th edition, Who’s Who in the World, and Philadelphia Magazine’s “Top Docs,” among others.
Sara Laskey, MD
Chief Patient Experience Officer MetroHealth
Dr. Sara Laskey, MD, was named the first Chief Patient Experience Officer at Cleveland’s MetroHealth System in late 2013. In this position, Dr. Laskey is responsible for the leadership, design, and implementation of initiatives that fulfill the patient-centered mission and vision of MetroHealth. She collaborates with MetroHealth executives, medical staff, and department directors to develop and implement best practices, training programs and communications that are transforming the culture of MetroHealth.
In the past three years, Dr. Laskey and her team developed and implemented Pathways to Patient Experience and Pathways to Caring two innovative training programs that emphasized culture, values and service recovery. She has launched a recognition program, “Star IQ Genius,” to honor those employees whose behavior is exemplary of patient-centered care as well as implementing data driven “Executive Rounding” for administrative and clinical leaders throughout the organization. Dr. Laskey has also spearheaded the full transparency of her organization with the publication of ratings and reviews of providers and service lines on their website. They are changing the focus of their patient metrics from a CAHPS driven model to one of patient retention and loyalty with a focus on timely feedback that can be adjusted according to the needs of the customer and the organization. The Office of Patient Experience encompasses seven departments including Patient Centered Healthcare, Volunteer Services, Arts-in-Medicine, Patient Relations, Language Access/Customer Service, Pastoral Care and Survivor Recovery Services.
In addition to her Patient Experience responsibilities, Dr. Laskey is also an active attending physician in the Emergency Department at MetroHealth and previously was the Director of Medical Operations for the department, a position she held from 2011 through 2013. She is an assistant professor at Case Western Reserve School of Medicine. Her undergraduate degree is in performance studies from Northwestern University. She has also studied at The Second City in Chicago and earned a BFA (bachelor of Fun arts) from Ringling Bros. and Barnum & Bailey Clown College. She performed as a circus clown with the Greatest Show on Earth from 1988-1990.
About MetroHealth: The MetroHealth System, with more than 500 primary care and specialty care physicians, is one of the most comprehensive healthcare providers—and the only level one trauma center—in Northeast Ohio. As a public healthcare system, MetroHealth provides services to any resident of Cuyahoga County regardless of ability to pay. MetroHealth also is a center for medical research and education, affiliated with Case Western Reserve University School of Medicine. All staff physicians hold faculty appointments with Case Western Reserve.
Program Director, Specialty Pharmacy Vanderbilt Medical Center
With more than 13 years of Specialty Pharmacy experience, Brandon has served in various roles at Accredo, Medco, Express Scripts and Vanderbilt Specialty Pharmacies. In 2012 he piloted the “Embedded Specialty Pharmacist” model that Vanderbilt uses in its clinics today to provide comprehensive and coordinated care to specialty patients. As Program Director of VSP, his focus is on business growth opportunities including payer and manufacturer contracting. Brandon is a board member for the Specialty Pharmacy Certification Board and also serves on the NASP education committee.
Vice President, Managed Care, Specialty, Hub Horizon Pharma
Roxanne Schwans, MBA, is Vice President, Managed Care Market Access, HUB and Specialty Pharmacy for Horizon Pharma. She is responsible for Managed Care, PBM, HUB and specialty contracts for orphan, commercial and specialty drugs as well as their distribution.
During Roxanne’s 24 years of innovative leadership, she has consistently exceeded forecast goals and increased profitability while showing an extraordinary level of creativity and strategic insight. Her high-level executive tenures at Walgreens, Amgen Biologics, Hospital Corporation of America, Sanofi-Aventis and Johnson and Johnson were marked by the development of cadres of strong leaders, and she helped her teams develop valuable best practices while establishing measurable efficiencies.
An expert in strategic planning, marketing and sales, Roxanne has created and implemented numerous highly innovative marketing programs and ad campaigns along with large contracts, patient services and HUB consolidation projects. With her powerful communication skills, she connects as well with consumers as with C-Suite executives.
Winner of both the Payer Leadership Award and Excellence in Achievement Award,
Roxanne’s expertise includes strategy, sales, legal, sales operations, HUB, specialty pharmacy, client services, government and national accounts. She has implemented astute marketing strategies for national managed care organizations, health systems, clinics, employers, brokers, government entities, HUB services, unions and PBMs.
A Six Sigma Green Belt, Roxanne is an executive board member of the ADA of South Dakota and the Pennsylvania Bio Executive Team. She holds an MBA, a Health Services Administration BS degree, and is a board certified radiologic technologist.
Patient Services Sandoz; Former
Patient Access Otsuk
Kesslyn Smith is an experienced leader in the building of innovative, patient-centric reimbursement and patient support programs. She has served patients across a broad range of disease states at Sanofi and its predecessor companies, at Otsuka, and more recently at Sandoz Biopharmaceuticals where she designed, developed and launched a comprehensive reimbursement support program for the first Biosimilar product in the U.S.
Kesslyn initially made her mark in Oncology where she was responsible for strategic oversight and management of initiatives in oncology patient assistance, national patient advocacy programs, and support programs for the underinsured, including co-pay assistance. She has also held positions in oncology clinical operations and global marketing.
Kesslyn is a respected and admired advocate in the patient access community, where she has served on several strategic advisory committees. In addition, she has chaired large industry events and is a key industry speaker on topics such as healthcare reform, affordability, specialty distribution and an array of other topics related to supporting patients’ needs.
Kesslyn also is the recipient of several industry awards including Patient Advocate Foundation’s “Humanitarian Advocacy Award”, and in 2013 she was the inaugural recipient of AmerisourceBergen “Commitment to Patient Care” Award, honoring one individual who has spent their career advocating for patient access and outcomes and has been able to achieve results.
Director Specialty marketing and market access pfizer
Stephen currently serves as Director, Specialty Injectable Marketing and Market Access functions within the Pfizer Injectables business unit, a $1.1 billion portfolio supplier of sterile injectables and surgical products. In this role, he provides leadership in the establishment and maintenance of product value propositions inclusive of commercialization, pricing, distribution, access, reimbursement, patient services, and dispensing of Specialty Products.
Stephen brings close to 26 years of managed care and marketing experience largely in the US. In his prior position as Associate Director of Brand Maximization and Established Medicines at Novartis Pharmaceuticals, he led brand and portfolio peri-LOE teams on initiatives to improve product access, reimbursement, patient affordability, and emerging customer strategy across the portfolio of cardiovascular, oncology, immunology, anti-infective, inflammatory, neuroscience, and pipeline assets across the product life cycle. He also served as market access, distribution, and pricing lead for ILARIS, where he developed customized distribution strategies, market access plans, and reimbursement programs.
Prior to Novartis, Stephen has served in a number of cross-functional roles with Pharmacia/Upjohn, Johnson & Johnson, and Bristol Myers Squibb leading the generation of optimal access and reimbursement for products across multiple managed care accounts. These include GPOs, IDNs, ACOs, PBMs, SPPs, Retail, Wholesalers, Insurers, VA/DoD and other national/regional customers across all channels such as Commercial, Medicare Part D/B, Managed Medicaid and ACA Exchanges. In these positions, he has developed a deep knowledge and understanding of the clinical, economic, and business model dynamics driving decision making and product coverage by payers.
Stephen’s managed care, marketing, pharmaceutical launch, and lifecycle management expertise in US product commercialization also spans biologics, small molecules, devices, biosimilars, and generics across multiple therapeutic classes including rare diseases.
Stephen holds a B.S. in Biology from Wright State University and an M.B.A. from Franklin University, as well as attending executive leadership programs in pharmaceuticals & leadership at Harvard School of Business.
Senior National Managed Markets Director Alkermes
Mark has over twenty-five years of experience in pharmaceutical sales, pharmaceutical sales management, managed care, national account management, and business development. Mark has been directly involved with the launch, sale, access/reimbursement, and distribution of specialty injectable products since 1998. While currently with Alkermes, Mark has spent time at The Upjohn Company (Pharmacia), MedImmune, and Intercell.
Vice President Patient Experience UCB
Douglas Stover joined UCB in 2016 to lead the Patient Experience and Value Mission for the Global Neurology Patient Value Unit.
Prior to joining UCB, Douglas spent 10 years with Gallup, a research based consultancy, where he served as a strategic advisor to clients building customer focused cultures. During his time a Gallup, he was also responsible for the overall success of the joint venture between Gallup and Healthways, Inc., whose mission was to redefine how individuals, organizations, communities and countries measure and manage well-being. Previous experience includes senior positions at The Advisory Board, OgilvyOne and ICG Commerce.
Douglas received his Bachelors of Science from the Pennsylvania State University and Masters of Business Administration from Georgetown University.
Senior Director, Global Medical Affairs Teva
Dr. Tang is the Senior Director and Head of Growth Markets, Global Health Economics and Outcomes Research (GHEOR) at Teva Pharmaceutical, responsible for health outcomes research in developing countries and Asia region. Dr. Tang has established the newly created Growth Markets Market Access and HEOR team within Teva.
Previous, Dr. Tang was a Senior Director of Health Outcomes Research at Pfizer Emerging Markets supporting Asia region. His responsibilities includes developing and implementing research strategies in clinical development (specialized in health economics assessment and patient reported outcomes, product value dossiers), and post market products (real world and large database creation and analysis). Dr. Tang is specialized in therapeutic areas of oncology, hematology, and immunology (biologics), and women’s health.
Prior to Pfizer, Dr. Tang was the director of Health Economics and Clinical Outcomes Research in Johnson & Johnson and GlaxoSmithKline, where he was responsible for health outcomes research in biologics and oncology.
He is also an adjuvant professor of China Fudan University, adjuvant faculty of Zhejiang University Medical School, and Scholar of School of Population Health, Thomas Jefferson University. Meanwhile, Dr. Tang is the current Chair of the Health Technology (Industry) Committee, Asia Consortium of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR).
Dr. Tang’s training includes a medical degree in Preventive Medicine, PhD in Health Services Research, and MPH in Health Planning and International Health.
He has over 20 years’ experiences in medicine, public health, and health economics and outcomes research. He has published more than 30 manuscripts in peer review journals, 100+ abstracts and numerous speeches and presentations in major scientific congresses including ISPOR. He is knowledgeable in the development of Health Technology Assessment around the world. In addition, he served at Scientific Committees of International Health Economics Association (iHEA), Society for Medical Decision Making (SMDM), and a Peer Reviewer of America Journal of Managed Care.
Head of Patient Access and Services Jazz Pharmaceuticals
Stella K. Vnook is a Head of Access Services and Patient Support at Jazz Pharmaceuticals. Responsible for leading two critical components of the Market Access function at Jazz: Patient Services and the Field Access Managers (focused on Hematology/ Oncology, Sleep/ Narcolepsy, Pain Franchises). With her leadership, Jazz team will optimize patient services program’s design and delivery with an evidence-based approach to optimize patient access.
From 2014-2017 Stella was a Head of Managed Markets at Purdue Pharma, where she successfully re-shaped Market Access Division; infusing a new payer strategy and contracting analytics around profitable access. Her scope of responsibilities included Commercial, Pharmacy, Government and Institutional channels for Purdue’s Sleep, Pain, OIC and OTC Franchises.
At Blackstone Private Entity, Catalent, Stella accelerated revenue growth and helped the company file an IPO in early 2014. Heading up the Global Marketing and Strategy for Softgel Technology (B2B), her teams developed and implemented highly successful marketing programs to launch 9 products, build 2 Joint Ventures and led numerous acquisitions in LATAM, Asia-Pacific and EU to further growth Rx and Consumer brands for Catalent.
At Merck, she led the new commercial strategy efforts as a Director of US Strategy Office, focusing on customer centricity, integration of Schering Plough and other critical M&A activities. As part of Merck, and Schering-Plough Joint Venture, she formed new managed markets organization, launched multiple brands, re-engineered sales structures to fit the needs of JV which led to immediate success in gaining profitable access, drive product launch efficiency and create patient and provider awareness of product benefits.
Stella holds a B.A. in Biology & Anthropology, a Pharmacy Degree from Temple University (PA License) and M.B.A. from LaSalle University. She is certified in Six Sigma (Green Belt), Lean Sigma and Organizational Change Management.
Marla Wexler is 35 years old, was born with a complex congenital heart defect, and had 4 open-heart surgeries by the time she was 6. She went from pediatric cardiac ICU patient to pediatric cardiac ICU nurse until being diagnosed with systemic lupus erythematous (lupus). Due to complications from the disease, she was forced to put her nursing career on hold. Since 2008, Marla has been diagnosed with lupus and multiple rare autoimmune diseases, cervical cancer, and lobular carcinoma in situ.
She’s the creator and author of the blog Luck Fupus (www.luckfupus.com) which she writes about the day-to-day and long-term struggles of living with multiple chronic illnesses. She’s known for her humorous, keep-it-real style of writing. Her blog was used as a platform to help her become a patient leader and influencer, and Marla now travels the country attending healthcare conferences, speaking publicly sharing her story, educating and advocating for patients across the globe.
Tonya A. Winders, MBA
President and CEO Allergy and Asthma Network Global Allergy & Asthma Patient Platform
Tonya Winders. MBA is currently the President and Chief Executive Officer of Allergy &
Asthma Network, the leading patient advocacy organization dedicated to ending needless
death and suffering due to asthma, allergies and related conditions.
Tonya has over 17 years experience in leadership roles within the allergy and asthma
industry. From sales and marketing leadership to managed markets access, she has worked
tirelessly to ensure patients have access to effective diagnostic and treatment tools.
Tonya serves on several expert panels including NAEPP and NIAID Immunotherapy
Utilization. Furthermore, she is on the board of directors of Not One More Life, American
Respiratory Care Foundation and is the current president of the Global Asthma & Allergy
Personally, Tonya is the mother of five children, four of whom have asthma and/or allergies,
ranging in age from 12-18 years old. She is a fierce patient advocate who overcame cancer
twelve years ago. She now enjoys spending time with her husband of twenty years Brian
Winders and cheering on her children in various sports.